Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis
- PMID: 29083080
- DOI: 10.1111/imj.13667
Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a common cause of incidental liver test abnormalities. General practitioners (GP) have a key role in identifying people with NAFLD at risk of significant liver disease. Recent specialist guidelines emphasise the use of fibrosis algorithms or serum biomarkers rather than routine liver tests, to assess advanced fibrosis.
Aim: To evaluate primary care clinicians' current approach to diagnosis, management and referral of NAFLD.
Methods: A cross-sectional survey of primary care clinicians was undertaken through a structured questionnaire about NAFLD. A convenience sample of general practice clinics and general practice conferences in Metropolitan Brisbane and regional south east Queensland was selected.
Results: A total of 108 primary care clinicians completed the survey (participation rate 100%). Fifty-one percent of respondents considered the prevalence of NAFLD in the general population to be ≤10%. Twenty-four percent of respondents felt that liver enzymes were sufficiently sensitive to detect underlying NAFLD. Most respondents were unsure whether the Fibrosis 4 score (62.7% unsure) or Enhanced Liver Fibrosis score (63.7% unsure) could help to identify advanced fibrosis or cirrhosis. Although 47% of respondents said they would refer a patient to a Gastroenterologist/Hepatologist if they suspect the patient has NAFLD, 44.1% do not make any referrals. Of concern, 70.6% of clinicians said they were unlikely to refer a patient to Hepatology unless liver function tests are abnormal.
Conclusion: Our findings demonstrate that many primary care clinicians underestimate the prevalence of NAFLD and under-recognise the clinical spectrum of NAFLD and how this is assessed.
Keywords: Enhanced Liver Fibrosis test; general practice; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; transient elastography.
© 2017 Royal Australasian College of Physicians.
Similar articles
-
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.Dig Dis Sci. 2018 Sep;63(9):2259-2266. doi: 10.1007/s10620-018-5123-3. Epub 2018 May 19. Dig Dis Sci. 2018. PMID: 29779083
-
Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.World J Gastroenterol. 2015 Oct 21;21(39):11077-87. doi: 10.3748/wjg.v21.i39.11077. World J Gastroenterol. 2015. PMID: 26494963 Free PMC article. Review.
-
EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?Diabetologia. 2017 Jul;60(7):1218-1222. doi: 10.1007/s00125-017-4264-9. Epub 2017 Mar 28. Diabetologia. 2017. PMID: 28352941
-
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.J Hepatol. 2020 Jan;72(1):14-24. doi: 10.1016/j.jhep.2019.08.027. Epub 2019 Sep 10. J Hepatol. 2020. PMID: 31518646
-
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.Clin Liver Dis. 2018 Feb;22(1):73-92. doi: 10.1016/j.cld.2017.08.004. Clin Liver Dis. 2018. PMID: 29128062 Review.
Cited by
-
European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?JHEP Rep. 2021 Jan 21;3(2):100234. doi: 10.1016/j.jhepr.2021.100234. eCollection 2021 Apr. JHEP Rep. 2021. PMID: 33733078 Free PMC article.
-
Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD/MAFLD).J Clin Med. 2024 Aug 17;13(16):4857. doi: 10.3390/jcm13164857. J Clin Med. 2024. PMID: 39200999 Free PMC article. Review.
-
Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?Diagnostics (Basel). 2022 Dec 28;13(1):91. doi: 10.3390/diagnostics13010091. Diagnostics (Basel). 2022. PMID: 36611384 Free PMC article. Review.
-
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.J Clin Med. 2023 Sep 26;12(19):6216. doi: 10.3390/jcm12196216. J Clin Med. 2023. PMID: 37834859 Free PMC article. Review.
-
Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment.Clin Med (Lond). 2020 May;20(3):313-318. doi: 10.7861/clinmed.2019-0250. Clin Med (Lond). 2020. PMID: 32414722 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical